StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
IMNMImmunome Inc.
stockpulse.co.kr
Nasdaq
$17.99▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.04BShares out 1.100M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

19
  • 10.5Pre-market26.10.05 21:30
    8-KKey event#●●●#●●●#●●●

    Immunome Inc.Bullish

    Immunome has amended its license agreement with Bristol-Myers Squibb (BMS) to acquire full patent rights related to varegacestat and AL101. As consideration, the company paid $20 million in cash and issued 4,425,487 shares of common stock, effectively eliminating all future milestone and royalty payment obligations under the agreement.…more

    $17.99+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.15After-hours26.09.16 05:30
    4Ownership

    Immunome Inc.

    Insider Jack Higgins of Immunome Inc. reported a change in beneficial ownership of securities as of September 11, 2026. This filing provides the details of the insider's equity position change via Form 4.…more

    $17.99+0.00%vs prev close
    View filingShare
  • 9.11Regular26.09.11 23:20
    144Ownership

    Immunome Inc.

    Jack Higgins, an insider at Immunome Inc., has filed an SEC Form 144 to report the proposed sale of company shares. This is a standard filing disclosing the insider's plan to dispose of their equity holdings.…more

    $17.99+0.00%vs prev close
    View filingShare

18 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 10.5Pre-market26.10.05 21:34
    #●●●#●●●

    Immunome Enters Fourth Amendment to License Agreement with Bristol-Myers Squibb…more

    Immunome has entered into the fourth amendment to its license agreement with Bristol-Myers Squibb. As the specific terms and financial implications were not disclosed, this is considered a neutral development.…more

    $17.99+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 9.30Pre-market26.09.30 20:46

    ●●●●●●●● ●●●●● ●●●●●●

    Immunome has received FDA clearance for its Investigational New Drug application for IM-1340, a potential first-in-class ADC for advanced solid tumors. This approval allows the company to advance its targeted cancer therapy into clinical trials.…more

    $17.99+0.00%vs prev close
    ShareBenzinga

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →